NCT04706598View on ClinicalTrials.gov

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

July 11, 2024

Study Completion Date

December 31, 2024

Conditions
Urinary Bladder NeoplasmsImmunotherapy
Interventions
DRUG

Camrelizumab

Solution for Infusion (Intravesical)

Trial Locations (4)

200011

Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai

200032

Fudan University Shanghai Cancer Center, Shanghai

200072

Shanghai Tenth People's Hospital,Shanghai Tong Ji University School of Medicine, Shanghai

200080

Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Shen Kang Hospital Development Center

OTHER

lead

Fudan University

OTHER